Monday’s Top Health Care Stories: Medtronic, Covidien, Bluebird Bio, and Gilead Sciences

Medtronic, Covidien, Bluebird Bio, and Gilead Sciences could make waves across the health care sector this Monday morning.

Jun 16, 2014 at 9:12AM

Longview

Let's take a look at four companies -- Medtronic (NYSE:MDT), Covidien (NYSE:COV), Bluebird Bio (NASDAQ:BLUE), and Gilead Sciences (NASDAQ:GILD) -- which could all loom large in health care headlines this Monday morning.

Medtronic buys Covidien for $42.9 billion
Medtronic just confirmed that it will purchase Covidien in a $42.9 billion cash and stock deal valuing the company at $93.22 per share -- a premium of nearly 30% from Covidien's closing price last Friday. Each share of Covidien will be converted into the right to receive $35.19 in cash and 0.956 shares of Medtronic. Shares of Medtronic are up 11%, and shares of Covidien are up 34% in pre-market trading this morning.

Medtronic shareholders will benefit from the acquisition in two major ways.

First, the deal allows Minneapolis-based Medtronic to move its tax domicile to Dublin, Ireland, where Covidien is incorporated. That strategy, known as tax inversion, will permit Medtronic to pay a much lower corporate tax rate than in the U.S.

Second, Covidien's three business segments -- surgical solutions, vascular therapies, and respiratory and patient care -- fit well into Medtronic's Cardiac and Vascular Group and Restorative Therapies Group, which together accounted for 90% of its top line last quarter. Medtronic believes that the acquisition will become earnings accretive in the first fiscal year and achieve $850 million in annual pre-tax cost synergies by the end of fiscal 2018.

Bluebird Bio takes flight on positive initial results for LentiGlobin
Shares of Bluebird Bio are up more than 68% in pre-market trading this morning, after the company reported positive initial results for its gene therapy candidate LentiGlobin as a treatment for beta-thalassemia major, a blood disorder characterized by the excessive destruction of red blood cells leading to anemia.

One patient in Bluebird's LG001 trial and two patients in its HGB-205 study showed statistically significant increases in total hemoglobin, and were able to be weaned off of blood transfusions.

LentiGlobin is currently in phase 1/2 trials in the U.S. and France for the beta-thalassemia indication. BlueBird recently initiated a larger LentiGlobin trial for beta-thalassemia in the U.S. which will enroll 15 patients, and expects to report updated data from these studies by the end of the year.

Bluebird's most advanced pipeline candidate is Lenti-D, a potential treatment for Childhood Cerebral ALD (Adrenoleukodystrophy), a central nervous system disorder. The company went public last June at an IPO price of $17.00 per share.

Gilead Sciences reports positive top-line results in Japan for its HCV combo
Last but not least, Gilead Sciences just reported positive top-line results from a phase 3 trial in Japan evaluating a once-daily fixed-dose combination of Sovaldi and the NS5A inhibitor ledipasvir (with and without ribavirin) in patients with hepatitis C (HCV).

100% of the patients in both the treatment-experienced and treatment-naive groups receiving the combination treatment without ribavirin achieved a sustained virologic response 12 weeks after the end of the therapy. 96% of treatment-naive patients and 100% of treatment-experienced patients receiving the combination with ribavirin achieved a sustained virologic response. Across all arms of the study, 99% of patients with cirrhosis achieved a sustained virologic response.

Based on that positive data, Gilead plans to submit a new drug application (NDA) for the ledipasvir and Sovaldi combination with the Japanese Pharmaceutical and Medical Devices Agency by the end of 2014. Sovaldi was approved in the U.S. last December and in the E.U. in January. The drug generated $2.27 billion in sales last quarter -- beating average analyst estimates by more than $1 billion.

Although this positive development doesn't address the main issue with Sovaldi -- its controversial $84,000 price tag for a full 12-week treatment -- it indicates that Gilead could successfully use Sovaldi as the foundation for a new generation of combo HCV treatments, just as it previously used Viread to develop a portfolio of blockbuster HIV drugs.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster, CLICK HERE NOW.

Leo Sun owns shares of Gilead Sciences. The Motley Fool recommends Covidien and Gilead Sciences. The Motley Fool owns shares of Gilead Sciences and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers